AMYPAD PNHS

The AMYPAD Prognostic and Natural History Study added amyloid PET to people already followed in European cohorts of adults without dementia, to study how amyloid builds up in the preclinical phase of Alzheimer's disease. It was part of the IMI 2 project AMYPAD, and Amsterdam UMC holds the data. Participants stay in their parent cohort, which supplies cognition, biomarkers, MRI and risk factors, while AMYPAD provides the PET scans. The study is moving into the Euro-PAD community.

Composition

The harmonised release integrates 3,368 participants from 10 parent cohorts, among them EPAD LCS, EMIF-AD 60++ and 90+, ALFA+, FACEHBI, F-PACK, DELCODE and the AMYPAD diagnostic study. Of these, 1,620 had a baseline amyloid PET and 888 at least one follow-up PET. The MRI data descriptor covers 2,759 cognitively normal or mildly impaired people with longitudinal scans. A separate raw release holds 3,266 participants from nine cohorts. Tables cover demographics, cognition, CSF, APOE and polygenic scores, vital signs, medical history and lifestyle.

Acquisition

Sites are in Belgium, France, Germany, Spain, Sweden, Switzerland, the Netherlands and the United Kingdom. PET used [18F]florbetaben or [18F]flutemetamol, as static or dual-time-window dynamic scans, with reconstructions harmonised using Hoffman phantom scans across the 28 PET scanners of the AMYPAD studies. MRI comprises core T1w, T2w, T2* and FLAIR and advanced SWI, resting-state fMRI, diffusion and ASL sequences. Raw and processed images are shared as NIfTI in BIDS layout.

Annotations

PET scans carry blinded visual reads and Centiloid, SUVR and kinetic values. MRI comes with visual ratings (atrophy scales, Fazekas, lacunes, microhaemorrhages, infarcts), BaMoS white matter hyperintensity segmentations, FreeSurfer measures and diffusion, perfusion and connectivity phenotypes. No voxel-level microbleed labels are described.

Known limitations

• Data come from 17 sites, and participants entered at different points of their parent cohort follow-up.
• Raw data need approval from every contributing parent cohort, and only group-level derived data may be shared.
• Scanner vendors, field strengths and per-sequence counts are not stated in the public sources used here.